12:00 AM
 | 
Jun 25, 2012
 |  BC Week In Review  |  Clinical News  |  Clinical Results

ReN001: Phase I data

Interim data from 5 patients with moderate to severe functional neurological impairments resulting from stroke in the open-label, dose-escalation, U.K. Phase I PISCES trial showed that single doses of intracranial ReN001 led to no cell-related adverse events or adverse immune-related responses at 3 (n=2), 6 (n=1) or 12 months (n=2) post-treatment. There were minor procedure-related adverse events, including asymptomatic bleeds and superficial scalp infections at the implantation site. Additionally, ReN001 improved neurological...

Read the full 336 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$30 USD
More Info >